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Abstract PCR-based subtractive hybridisation was used to
identify genes up-regulated when pericytes undergo osteogenic
differentiation and deposit a calcified matrix. cDNA pools were
generated from confluent pericytes and from pericyte cultures
containing calcified nodules. A pericyte cDNA library was
screened with the product of the subtraction procedure (calcified
minus confluent cDNA) and the majority of the positive clones
were identified as matrix Gla protein (MGP). Northern analysis
and immunohistochemistry demonstrated that MGP was only
expressed by pericytes in calcified nodules. Antibodies to MGP
inhibited the deposition of a calcified matrix by pericytes,
suggesting that MGP regulates both cell differentiation and
calcification. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Pericytes are an integral part of the microvasculature, where
they partially surround endothelial cells sharing a common
basement membrane [1]. Pericyte-like cells have also been lo-
calised in the sub-endothelial and medial layers of large, me-
dium and small human arteries as well as in the vasa vasora of
the adventitia [2]. There is good evidence to suggest that peri-
cytes have osteogenic potential in vivo and in vitro, and it has
been proposed that these cells may play a role in the growth,
maintenance and repair of the skeleton and in diseases involv-
ing ectopic calci¢cation [3^6]. Indeed, several recent studies
have highlighted the potential role of pericytes, or pericyte-
like cells present in arteries, in mediating the calci¢cation as-
sociated with atherosclerosis [7,8].
Vascular pericytes display a distinctive and reproducible
pattern of growth and di¡erentiation in vitro [6]. After reach-
ing con£uence, these cells form multicellular nodules. Crystals
of hydroxyapatite are then deposited on the extracellular ma-
trix of these nodules [3,4]. We have demonstrated that this
process is associated with the stage-speci¢c expression of
markers of primitive clonogenic marrow stromal cells
(STRO-1), and markers of cells of the osteoblast lineage
(bone sialoprotein, osteocalcin, osteonectin, osteopontin and
type I collagen) [5,6]. However, the regulation of pericyte
di¡erentiation is by no means understood.
In this study we have used PCR-based subtractive hybrid-
isation to identify genes that are switched on as pericytes
di¡erentiate into bone-forming cells and deposit a calci¢ed
matrix. The majority of the positive clones were identi¢ed as
matrix Gla protein (MGP), a small Gla-containing protein
previously shown to accumulate in adult bone, cartilage and
dentin [9]. We demonstrate that MGP is di¡erentially ex-
pressed during the di¡erentiation of pericytes in vitro, and
that antibodies to MGP inhibit the deposition of a calci¢ed
matrix by these cells. These results are discussed in terms of
the proposed roles of MGP in regulating cell di¡erentiation
and calci¢cation.
2. Materials and methods
2.1. Cells and culture conditions
Pericytes were isolated from adult bovine retinal microvessels, char-
acterised and cultured as previously described [5]. The results pre-
sented herein were obtained using 20 di¡erent preparations of bovine
retinal pericytes at ¢rst or second passage.
2.2. RNA isolation and analysis
RNA was isolated from (i) sub-con£uent pericytes (day 4 post-plat-
ing), (ii) con£uent pericytes (days 7^10 post-plating), (iii) post-con£u-
ent cultures containing small non-calci¢ed nodules (days 14^25 post-
plating), (iv) post-con£uent cultures containing calci¢ed nodules (days
30^45 post-plating) and (v) from puri¢ed pericyte nodules [5].
2.3. Ampli¢cation of cDNA
PolyA cDNA with an average length of 400 bases was generated
using the puri¢ed pericyte RNA as described [5,10].
2.4. Subtractive hybridisation
Subtractive hybridisation was performed to isolate genes that were
up-regulated during the osteogenic di¡erentiation of vascular pericytes
[10]. A 20-fold molar excess of polyA cDNAs prepared from con£uent
pericytes was photobiotinylated and mixed with non-biotinylated tar-
get cDNAs prepared from post-con£uent pericytes. After boiling to
denature the double-stranded DNA and hybridisation, all biotinylated
hybrids were removed using avidin/organic extraction. Residual target
cDNA was ampli¢ed and subjected to four further rounds of subtrac-
tion. The polyA cDNA obtained from the ¢nal round of the subtrac-
tion procedure was used to screen a custom-made Lambda ZAP-II
cDNA library prepared from pericyte mRNA extracted from cultures
containing cells at all stages of their growth and di¡erentiation (Stra-
tagene Ltd, Cambridge, UK). Filters were hybridised overnight at
37‡C with a 32P-labelled subtracted cDNA probe. The ¢lters were
washed with 0.5USSC/0.1% SDS at 37‡C, and exposed to X-ray
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¢lm (Fuji) at 380‡C with intensifying screens. Puri¢ed positive phage-
mids were isolated from the Lambda ZAP II vector using the Ex-
Assist/SOLR system (Stratagene). Plasmids of interest were puri¢ed
and sequenced on an ABI Prism 377 sequencer using a PCR-based
dye terminator sequencing kit (Perkin Elmer).
2.5. Random labelling of cDNA probes
Hybridisation probes were prepared by random labelling 50 ng
DNA with [K-32P] dCTP using an oligolabelling kit (Amersham Phar-
macia Biotech, UK).
2.6. Southern blotting
Ampli¢ed cDNAs (5^10 Wl per lane) were electrophoresed in 1.5%
agarose in Tris-borate bu¡er, denatured in NaOH/NaCl, neutralised
in Tris^HCl/NaCl and transferred to Hybond N nylon membranes.
Tracks containing control samples for the PCR reaction did not stain
with ethidium bromide. Filters were hybridised with 32P-labelled
probes at 65‡C overnight, washed at high stringency (0.2USSC,
0.1% SDS at 65‡C) and exposed to X-ray ¢lm at 380‡C.
2.7. Northern blotting
Samples of RNA (15 Wg) were separated in 1.2% agarose gels con-
taining 2.2 M formaldehyde, transferred to Hybond N nylon mem-
branes and ¢xed by baking for 1 h at 80‡C. Filters were pre-hybrid-
ised and hybridised with 32P-labelled probes at 65‡C in phosphate
bu¡er containing 1% BSA and 7% SDS [11]. Filters were washed in
2USSC, 1% SDS at 65‡C for 15 min, in several washes of 0.2USSC,
0.1% SDS at 65‡C for 1 h and exposed to X-ray ¢lm. This procedure
was repeated using RNA isolated from three di¡erent preparations of
pericytes.
2.8. Con¢rmation of speci¢city of anti-MGP serum
A rabbit polyclonal antibody raised against a C-terminal MGP
peptide (ERYAMVYGYNAAYNRYFRQRRGAKY) was kindly
provided by Dr G Karsenty (Houston, TX, USA). This antibody
has previously been shown to be speci¢c for MGP by ELISA (Dr
G. Karsenty, personal communication). The speci¢city of this anti-
body was con¢rmed by Western blotting. Growth plate and resting
zone (epiphyseal) chondrocytes were isolated from second trimester
bovine foetuses, separated by SDS^PAGE using a 12.5% gel under
reducing conditions, and transferred to nitrocellulose as described
[12]. E⁄cient transfer of protein was con¢rmed by soaking the nitro-
cellulose ¢lter in 0.2% (w/v) Ponceau S/3% (v/v) tri£uoroacetic acid
for 5 min. The ¢lter was blocked for 2 h in 1UPBS/0.05% (v/v) Tween
20 (PBS-T)/5% (w/v) non-fat dried milk. Primary antibody was added
at 1:250 dilution and incubated for 2 h at room temperature. The
¢lter was washed with PBS-T and then incubated with a horseradish-
peroxidase-conjugated swine anti-rabbit secondary antibody (1:2000
dilution, Dako, Denmark) for 1 h at room temperature. The ¢lter was
washed with PBS-T and the manufacturer’s instructions followed for
ECL1 detection (Amersham Pharmacia, St Albans, UK). The result
was visualised by exposure of the membrane to X-ray ¢lm (Kodak)
and developed using a Kodak automatic developer.
2.9. Immunolocalisation of MGP in pericyte nodules
Pericytes were cultured in standard culture medium until large,
calci¢ed nodules were present. Nodules were collected from the base
of the £ask using a sterile needle, snap-frozen and sectioned. Cryostat
sections (10 nm) were air-dried for 24 h, ¢xed in acetone (10 min), air-
dried for 40 min and then stored at 380‡C until use.
Immunohistochemistry was performed using a standard streptavi-
din biotin immunoperoxidase method (Duet kit, Dako, UK). The
anti-MGP antibody was used at a dilution of 1:200. Sections were
counterstained with haematoxylin. Negative controls included substi-
tution of the primary antibody with normal rabbit serum.
2.10. Addition of anti-MGP sera to pericyte cultures
Cultures were incubated in the presence of speci¢c antibodies
against MGP, as previously described [11]. Brie£y, pericytes (2U104
cells/cm2) were plated in 2 cm2 dishes, and cultured in standard
growth medium until (a) the cells were 80% con£uent or (b) small,
non-calci¢ed nodules were present. Anti-MGP antiserum was then
added to the culture medium (2 and 5 Wl antiserum per ml medium),
and the incubation continued for up to 33 days. Fresh antiserum was
added every time the medium was changed. Normal rabbit serum
(5 Wl per ml medium) was added to control wells. Cells were stained
with von Kossa, and both the total number of nodules present and the
number of calci¢ed nodules per culture was counted [11].
3. Results
3.1. Identi¢cation of genes up-regulated during pericyte
di¡erentiation
RNA was isolated from con£uent pericytes and from post-
con£uent cultures of cells containing calci¢ed nodules. PolyA
PCR was performed to produce cDNA representative of the
entire polyadenylated mRNA present in the two samples.
Subtractive hybridisation was then conducted to isolate
cDNAs which were speci¢cally up-regulated in the post-con-
£uent cultures. Ampli¢ed cDNA from con£uent pericytes
(Fig. 1, track 1), post-con£uent pericytes (Fig. 1, track 2)
and the four subtraction products (S1^S4; Fig. 1, tracks 3^
6) was electrophoresed on an agarose gel and subjected to
Southern hybridisation using 32P-labelled cDNA probes. The
ethidium bromide-stained gel (Fig. 1A) shows the amount of
cDNA loaded into each track of the agarose gel. Fig. 1B
shows the results obtained when this gel was probed with
S4 cDNA. This probe hybridised with samples in tracks 2^
6, but not with the sample in track 1 (from con£uent peri-
cytes). In comparison, the sample in track 1 hybridised
strongly with a con£uent pericyte cDNA probe (Fig. 1C). In
addition, the con£uent pericyte cDNA probe hybridised with
the sample in track 2 (from post-con£uent pericytes), demon-
strating that these two samples have many cDNAs in com-
mon. In contrast, the con£uent cDNA probe hybridised only
very weakly with the four subtraction products (tracks 2^6),
con¢rming that the majority of shared sequences were re-
moved by this procedure.
The subtracted cDNAs were then used to screen a pericyte
Fig. 1. Speci¢city of the subtraction product for poly(A) cDNAs
prepared from post-con£uent cultures of pericytes containing calci-
¢ed nodules. Samples of con£uent poly(A) cDNA (track 1), post-
con£uent poly(A) cDNA (track 2) and subtracted poly(A) cDNAs
(S1^S4, tracks 3^6 respectively) were electrophoresed on a 1.5% aga-
rose gel, visualised with ethidium bromide (A), and subjected to
Southern hybridisation with 32P-labelled S4 cDNA (B) or con£uent
cDNA (C).
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cDNA library. Positive plaques were identi¢ed, collected and
puri¢ed for further analysis as described in Section 2. One
clone, which hybridised strongly with the S4 cDNA probe,
was found to contain an insert of approximately 600 bp.
This clone was identi¢ed as MGP by PCR-based dye termi-
nator cycle sequencing.
3.2. Con¢rmation that MGP is di¡erentially expressed by
cultured pericytes
The level of MGP mRNA in cultured pericytes was exam-
ined by Northern blotting. RNA prepared from pericyte cul-
tures at di¡erent stages of their growth and di¡erentiation was
electrophoresed on an agarose gel and subjected to Northern
hybridisation using a cDNA probe for MGP. Fig. 2A con-
¢rms that MGP is only expressed by cells present in post-
con£uent cultures containing large calci¢ed nodules. MGP
mRNA was not detected in sub-con£uent pericytes, in con-
£uent pericytes or in pericyte cultures containing small non-
calci¢ed nodules. Fig. 2B con¢rms that similar levels of RNA
were loaded on each track of the agarose gel.
To con¢rm that MGP was expressed by cells presents in
pericyte nodules, immunolocalisation studies using speci¢c
antisera to MGP were performed. The speci¢city of this anti-
body was con¢rmed using Western blotting and immunohis-
tochemistry. Fig. 3 clearly demonstrates that the MGP anti-
serum reacts with a 15 kDa protein (approximately) in
proliferative zone chondrocytes, but not in resting zone chon-
drocytes (compare tracks 3 and 4). Furthermore, this anti-
body speci¢cally stains chondrocytes present in the proliferat-
ing and late hypertrophic zone of bovine growth plate
cartilage, and does not stain cells present in the zone of mat-
uration (results not shown). These data are consistent with
previous studies describing the localisation of MGP in carti-
lage [13,14]. Pericyte nodules were collected, snap-frozen, sec-
tioned and stained using this antiserum. Staining for MGP
was seen throughout the calci¢ed pericyte nodules (Fig. 4B).
Controls in which the ¢rst antiserum was substituted with
normal rabbit serum were negative (Fig. 4A).
Fig. 2. Expression of MGP during pericyte di¡erentiation. RNA
from post-con£uent pericytes containing large calci¢ed nodules
(track 1), post-con£uent pericytes containing small non-calci¢ed
nodules (track 2), con£uent pericytes (track 3) and sub-con£uent
pericytes (track 4) was subjected to Northern analysis. A: Hybrid-
isation with 32P-labelled cDNA probe for MGP. B: Ethidium bro-
mide-stained gel. The positions of 28S and 18S ribosomal RNA are
indicated.
Fig. 3. Western blot demonstrating the speci¢city of anti-MGP sera.
Lysates of bovine proliferative zone chondrocytes (tracks 1 and 3)
and resting zone chondrocytes (tracks 2 and 4) were separated by
SDS^PAGE and subjected to western blotting using anti-MGP sera
(tracks 3 and 4). Tracks 1 and 2 demonstrate equal transfer of pro-
tein onto the nitrocellulose ¢lter by Ponceau S staining. Track 3
demonstrates a single band at approximately 15 kDa (the predicted
weight of bovine MGP). There is no corresponding band in track 4,
indicating absence of MGP in resting zone chondrocytes. The pre-
stained molecular weight markers are indicated on the left.
Fig. 4. Immunolocalisation of MGP in pericyte nodules. A: Nega-
tive control. B: Section stained with antibodies to MGP.
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3.3. Antibodies to MGP inhibit calci¢cation of pericyte nodules
In the next series of experiments, the role of MGP in the
deposition of a calci¢ed matrix by pericytes was investigated.
Antibodies to MGP were added to either con£uent pericytes
or cultures of pericytes containing non-calci¢ed nodules, and
the e¡ects of these antibodies on the number of nodules
formed and the extent of calci¢cation of these nodules deter-
mined. Normal rabbit serum was added to parallel cultures as
a control.
Representative photomicrographs of cells incubated in the
presence and absence of antisera to MGP and stained with
von Kossa (which stains mineral deposits brown/black) are
shown in Fig. 5. These micrographs demonstrate clear di¡er-
ences in the extent of calci¢cation of pericyte nodules in con-
trol cultures (Fig. 5A) compared with those cultures incubated
with antisera to MGP (Fig. 5B,C). This experiment was re-
peated three times with two di¡erent populations of pericytes.
The total number of nodules formed and the extent of calci-
¢cation of these nodules were quanti¢ed as described in Sec-
tion 2, and the results obtained from a representative experi-
ment are shown in Fig. 5D. Antisera to MGP did not a¡ect
the total number of nodules formed in these cultures. How-
ever, antiserum to MGP reproducibly, and signi¢cantly, re-
duced the extent of calci¢cation of nodules in pericyte cul-
tures.
4. Discussion
Several lines of evidence suggest that MGP is a key regu-
lator of both cell di¡erentiation and calci¢cation [14,15].
Firstly, MGP is required for endochondral ossi¢cation as it
has been demonstrated that maturation of the growth plate is
disrupted if MGP is either deleted or over-expressed in vivo
[14,15]. Secondly, MGP inhibits the calci¢cation of cartilage.
Thus, the targeted deletion of MGP in mice results in the
spontaneous calci¢cation of the entire cartilage growth plate
[14] and over-expression of MGP in chick limb buds inhibits
cartilage calci¢cation [15]. Furthermore, patients with Keutel
syndrome, which is caused by mutations in the gene encoding
MGP, have abnormal cartilage calci¢cation [16]. Thirdly, it
has been claimed that the e¡ect of MGP on matrix calci¢ca-
tion is dependent upon the stage of di¡erentiation of the cells,
suggesting that this protein may have other roles in immature
cells [15].
The role of MGP in regulating calci¢cation of arteries is
less well understood. Firstly, mice de¢cient in MGP develop
normally but die shortly after birth as a result of medial
calci¢cation of all major arteries leading to blood vessel rup-
ture [14]. However, patients with Keutel syndrome have a
normal life expectancy with no increased risk of coronary
artery disease in the absence of functional MGP, suggesting
that medial calci¢cation is regulated by another mechanism in
humans [16]. Secondly, the level of expression of MGP in
normal and calci¢ed human arteries appears to be dependent
upon the type of calci¢cation present. Thus, MGP is detected
at low levels in normal blood vessels and is increased in pa-
tients with atherosclerosis where it is associated with calcium
and lipid in the intima [17]. In contrast, patients with medial
calci¢cation express lower levels of MGP than normal,
although the expression of this protein is focally increased
in a subset of smooth muscle cells adjacent to sites of calci¢-
cation [18]. Finally, the levels of MGP have been reported to
Fig. 5. E¡ect of antibodies to MGP on the production of a calci¢ed
matrix by pericytes. A: Control cells cultured in the presence of
normal rabbit serum (5 Wl). B: Cells cultured in the presence of 2 Wl
anti-MGP serum or (C) 5 Wl anti-MGP serum. D: The total number
of nodules present in the cultures and the percentage of these nod-
ules that were calci¢ed were determined. *P6 0.05 vs control and
normal rabbit serum. 2P6 0.001 vs control and normal rabbit se-
rum.
FEBS 24454 27-12-00 Cyaan Magenta Geel Zwart
A.E. Can¢eld et al./FEBS Letters 487 (2000) 267^271270
both decrease [19] and increase [20,21] during the calci¢cation
of vascular smooth muscle cells and calcifying vascular cells in
vitro. The reason for this discrepancy is not clear.
In this study, we have demonstrated that MGP is di¡er-
entially expressed when pericytes deposit a calci¢ed matrix
in vitro. Using Northern blotting and immunohistochemical
staining of pericyte nodules, we have con¢rmed that MGP is
only expressed in pericyte cultures containing large, calci¢ed
nodules. MGP is not expressed by con£uent pericytes. These
data are consistent with the studies of Tintut et al. [20] and
Proudfoot et al. [21] who demonstrated that the levels of
MGP increased as cells isolated from large blood vessels de-
posited a calci¢ed matrix, and these groups suggested that
(i) MGP was up-regulated in order to inhibit the extent
of calci¢cation or (ii) MGP inhibited calci¢cation until the
nodules developed to a form that facilitated calcium deposi-
tion [20,21].
The results of our functional studies using antibodies to
MGP now suggest an alternative explanation. If the sole func-
tion of MGP is to inhibit matrix calci¢cation, as suggested by
the gene deletion studies in mice, the addition of anti-MGP
serum to cultured cells should promote matrix calci¢cation as
these antibodies have been shown to have the same function-
blocking e¡ect as anti-sense MGP in cultured chondrocytes
(Newman, W., Wallis, G.A. and Grant, M.E., unpublished
information). However, our studies demonstrate that antibod-
ies to MGP inhibit the deposition of a calci¢ed matrix by
pericytes. These results support the suggestion that MGP
has a dual role in vascular cells, ¢rstly modulating cell di¡er-
entiation and subsequently controlling matrix calci¢cation. If
this is the case, antibodies to MGP may prevent pericytes
from reaching the point at which they calcify their matrix.
One possible explanation for this e¡ect is that the antibodies
inhibit the interaction between MGP and bone morphogenetic
proteins [22], which are synthesised by pericytes (Can¢eld,
A.E., unpublished observations) and calcifying vascular cells
[7]. Therefore, the evidence presented here and elsewhere
[15,16] suggest that the function of MGP is not as straightfor-
ward as originally proposed and further studies are needed to
fully de¢ne the mechanism by which MGP modulates both
vascular cell di¡erentiation and matrix calci¢cation.
Acknowledgements: The ¢nancial support of the Arthritis Research
Campaign is gratefully acknowledged. B.N. is a Clinical Training
Fellow supported by the Wellcome Trust.
References
[1] Sims, D.E. (1986) Tissue Cell 18, 153^174.
[2] Andreeva, E.R., Pugach, I.M., Gordon, D. and Orekhov, A.N.
(1998) Tissue Cell 30, 127^135.
[3] Schor, A.M., Allen, T.D., Can¢eld, A.E., Sloan, P. and Schor,
S.L. (1990) J. Cell Sci. 97, 449^461.
[4] Brighton, C.T., Lorich, D.G., Kupcha, R., Reilly, T.M., Jones,
A.R. and Woodbury, R.A. (1992) Clin. Orthop. Relat. Res. 275,
287^299.
[5] Doherty, M.J., Ashton, B.A., Walsh, S., Beresford, J.N., Grant,
M.E. and Can¢eld, A.E. (1998) J. Bone Miner. Res. 13, 828^838.
[6] Doherty, M.J. and Can¢eld, A.E. (1999) Crit. Rev. Eukaryot.
Gene Expr. 9, 1^17.
[7] Bostrom, K., Watson, K.E., Horn, S., Wortham, C., Herman,
I.M. and Demer, L.L. (1993) J. Clin. Invest. 91, 180^189.
[8] Can¢eld, A.E., Doherty, M.J., Wood, A.C., Farrington, C., Ash-
ton, B.A., Begum, N., Harvey, B., Poole, A., Grant, M.E. and
Boot-Handford, R.P. (2000) Z. Kardiol. 89, 20^27.
[9] Fraser, J.D. and Price, P.A. (1988) J. Biol. Chem. 263, 11033^
11036.
[10] Brady, G., Billia, F., Knox, J., Hoang, T., Kirsch, R., Voura,
E.B., Hawley, R.G., Cumming, R., Buchwald, M., Siminovitch,
K., Miyamaoto, N., Boehmelt, G. and Iscove, N.N. (1995) Curr.
Biol. 5, 909^922.
[11] Can¢eld, A.E., Sutton, A.B., Hoyland, J.A. and Schor, A.M.
(1996) J. Cell Sci. 109, 343^353.
[12] Green, H., Can¢eld, A.E., Hillarby, M.C., Grant, M.E., Boot-
Handford, R.P., Freemont, A.J. and Wallis, G.A. (2000) J. Bone
Miner. Res. 15, 1066^1075.
[13] Loeser, R., Carlson, C., Tulli, H., Gerome, W.G., Miller, L. and
Wallin, R. (1992) Biochem. J. 282, 1^6.
[14] Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Beh-
ringer, R.R. and Karsenty, G. (1997) Nature 386, 78^81.
[15] Yagami, K., Suh, J.-Y., Enomoto-Iwamoto, M., Koyama, E.,
Abrams, W.R., Shapiro, I.M., Paci¢ci, M. and Iwamoto, M.
(1999) J. Cell Biol. 147, 1097^1108.
[16] Munroe, P.B., Olgunturk, R.O., Fryns, J.-P., Maldergem, L.V.,
Ziereisen, F., Yuksel, B., Gardiner, R.M. and Chung, E. (1999)
Nature Genet. 21, 142^144.
[17] Shanahan, C.M., Proudfoot, D., Farzaneh-Far, A. and Weiss-
berg, P.L. (1998) Crit. Rev. Eukaryot. Gene Expr. 8, 357^375.
[18] Shanahan, C.M., Cary, N.R.B., Salisbury, J.R., Proudfoot, D.,
Weissberg, P.L. and Edmonds, M.E. (1999) Circulation 100,
2168^2176.
[19] Mori, K., Shioi, A., Jono, S., Nishizawa, Y. and Morii, H. (1998)
FEBS Lett. 433, 19^22.
[20] Tintut, Y., Parhami, F., Bostrom, K., Jackson, S.M. and Demer,
L.L. (1998) J. Biol. Chem. 273, 7547^7553.
[21] Proudfoot, D., Skepper, J.N., Shanahan, C.M. and Weissberg,
P.L. (1998) Arterioscler. Thromb. Vasc. Biol. 18, 379^388.
[22] Price, P.A. and Williamson, M.K. (1985) J. Biol. Chem. 260,
14971^14975.
FEBS 24454 27-12-00 Cyaan Magenta Geel Zwart
A.E. Can¢eld et al./FEBS Letters 487 (2000) 267^271 271
